Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma

Source: ECancer News, October 2018

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.

The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center.

Results of the study, the first randomized neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients, are reported in Nature Medicine.

Menu